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Nociceptin and its receptor (NOP) have been described as targets for the
treatment of pain and inflammatory diseases.1-3 However, mechanisms
contributing to the regulation of the nociceptin system are still not fully
understood. Toll-like receptors are a family of pattern recognition receptors
which play a central role during inflammation. TLR activation has been
reported to have an effect on opioid receptors and endogenous opioids.4,5
The aim of this study was to investigate the effects of TLR signaling on the
nociceptin system in human NB4 cells under inflammatory conditions.
• Human promyelocytic leukemia NB4 cells were stimulated with or without
different concentrations of phorbol-12-myristate-13-acetate (PMA).• Quantitative RT-PCR: mRNA expression of prepronociceptin (ppNOC),
NOP and TLRs (TLR2, TLR4, TLR7, TLR9).• Flow cytometry: Cell surface NOP, TLR2, TLR4 and intracellular
nociceptin, TLR7, TLR9 protein levels.• To investigate effects of TLR activation on ppNOC and NOP mRNA
expression, cells were cultured with or without PMA 5 ng/ml and with or
without agonists specific for TLR2 (lipoteichoic acid, LTA 10 μg/ml), TLR4
(lipopolysaccharide, LPS 1 μg/ml), TLR7 (imiquimod, IMQ 10 μg/ml) or
TLR9 (oligodeoxynucleotide [ODN] 2216 1 μM).• Statistics: median, interquartile range (IQR); Kruskal-Wallis test, Wilcoxon
signed-rank test, corrected for multiple testing; level of significance: p<0.05.
The present findings reveal additional details of the regulation of the
nociceptin system and nociceptin’s interaction with TLRs.
Activation of TLR7 and TLR9 signaling downregulates mRNA
expression of nociceptin and the nociceptin receptor in human NB4
cells under inflammatory conditions.
Elucidating the regulation of nociceptin and its receptor and the
mechanisms involved may lead to new insights into the treatment of
pain and/or inflammation.
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Nociceptin, NOP and TLRs (TLR2, TLR4, TLR7, TLR9) mRNA were
constitutively expressed and corresponding protein levels could be measured
in NB4 cells (Figure 1).
Figure 1. Nociceptin, NOP and toll-like receptor expression in NB4 cells.
PMA 0.1-300 ng/ml dose-dependently upregulated ppNOC and NOP mRNA
after 24 hrs. Based on these results, PMA 5 ng/ml was used in the
subsequent experiments. PMA upregulated ppNOC, NOP, TLR4 and TLR9
mRNA expression and downregulated TLR2 mRNA after 24 hrs compared to
controls (Figure 2).
Figure 3. mRNA expression of ppNOC, NOP in NB4 cells cultured with or
without PMA 5 ng/ml and with or without specific TLR agonists for 24 hrs.
The TLR7 agonist IMQ prevented PMA’s upregulating effects on ppNOC and
NOP mRNA expression. Cells stimulated with PMA and TLR9 agonist ODN
2216 showed an antagonistic effect on NOP mRNA compared to the
samples treated with PMA only (Figure 3). As for nociceptin and NOP
proteins, no changes were observed in NB4 cultured with PMA and different
TLR agonists compared to the PMA-treated samples.
*
Figure 2. mRNA expression of ppNOC, NOP and TLRs in NB4 cells cultured
with or without PMA 5 ng/ml for 24 hrs.
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